Market closedNon-fractional

Gossamer Bio/GOSS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Gossamer Bio

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Ticker

GOSS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

135

Gossamer Bio Metrics

BasicAdvanced
$240M
Market cap
-
P/E ratio
-$0.94
EPS
1.90
Beta
-
Dividend rate
$240M
1.9
7.127
6.823
736.543
782.325
-12.77%
-43.76%
19,905.42%
8.98
8.98
-1.24
-62.18%
-35.28%

What the Analysts think about Gossamer Bio

Analyst Ratings

Majority rating from 10 analysts.
Buy

Gossamer Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$42M
-12.89%
Profit margin
0.00%
NaN%

Gossamer Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.21
-$0.21
-$0.19
-
Expected
-$0.49
-$0.26
-$0.21
-$0.19
$0.33
Surprise
-7.98%
-17.84%
1.02%
0.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Gossamer Bio stock?

Gossamer Bio (GOSS) has a market cap of $240M as of July 23, 2024.

What is the P/E ratio for Gossamer Bio stock?

The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of July 23, 2024.

Does Gossamer Bio stock pay dividends?

No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of July 23, 2024.

When is the next Gossamer Bio dividend payment date?

Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.

What is the beta indicator for Gossamer Bio?

Gossamer Bio (GOSS) has a beta rating of 1.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Gossamer Bio stock

Buy or sell Gossamer Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing